분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-10-23 14:31:28 , Hit : 1288
 Novartis Extends Deal to Use SomaLogic Proteomics Technology


GEN News Highlights
Oct 20, 2014

Three years into a multi-year research agreement to use SomaLogic’s proteomics technology in its drug-development efforts, Novartis has extended the deal and will take an equity position in the privately held life-sci tools and clinical diagnostics developer.

Neither the value of the extended deal nor the length of the extension has been disclosed.

In a statement today, SomaLogic did say the companies agreed to “enhance and expand” efforts undertaken as part of the collaboration. Under their previous agreement, researchers at the Novartis Institutes for BioMedical Research (NIBR) and SomaLogic joined to build an enhanced version of SomaLogic's SOMAscan™ proteomics assay for NIBR, as well as develop specific SOMAmer® (Slow Off-rate Modified Aptamer) protein-binding reagents for multiple preclinical and clinical applications in NIBR’s research and development portfolio.

“Our ongoing relationship with Novartis is a model for how we seek to develop strong scientific collaborations that drive new discoveries and build value for both parties,” SomaLogic CEO Byron Hewett said in a statement.

SOMAmer reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of protein-binding reagents designed to combine the best properties of both monoclonal antibodies and traditional aptamers. They can be applied in many current preclinical and clinical analytical assays, including quantitative high-content screening, targeted panels, flow cytometry, histochemistry, functional assays, and biophysical methods.

No fewer than 1,129 different SOMAmer reagents are incorporated into SomaLogic’s commercially available SOMAscan assay, which is designed to efficiently, accurately, and rapidly measure proteins across a range of concentrations in just a few drops of blood or other tissues through binding to individual proteins and nucleic acid-based quantification.

SomaLogic offerings are intended to aid researchers in protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.  







967   피부암 외에도 다른 위험성이 있는 햇빛  이성욱 2014/10/24 1467
  Novartis Extends Deal to Use SomaLogic Proteomics Technology  이성욱 2014/10/23 1288
965   여성은 남성보다 현명한 의사결정자일까?  이성욱 2014/10/23 1460
964   스위칭 오프할 수 있는 리보자임(ribozyme)의 개발과 유전자치료 (우리실험실 결과소개)  이성욱 2014/10/17 2324
963   간에 암 전이가 어떻게 발생하는가  이성욱 2014/10/17 1677
962   CAR T 세포를 이용한 효과적인 항암 치료법  이성욱 2014/10/15 2059
961   Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval  이성욱 2014/10/14 1857
960   20년간 숨어 있던 폐암의 비밀  이성욱 2014/10/14 1461
959   특정 염색체 구조가 중요 유전자 조절  이성욱 2014/10/14 1839
958   초파리로 인체 대장암의 특징을 보여준다  이성욱 2014/10/12 1638
957   2014년 노벨 화학상: 세포의 내부생활을 드러낸 혁신적 현미경  이성욱 2014/10/12 2045
956   2014년 노벨 생리의학상 수상자  이성욱 2014/10/12 1427
955   CRISPR/Cas9 Can Now Edit RNA, Not Just DNA  이성욱 2014/10/07 1423
954   대장암 종양 성장과 밀접한 마이크로 알앤에이  이성욱 2014/10/06 1565
953   신약 개발을 위한 Cas9 동물 모델의 개발  이성욱 2014/10/02 1538
952   암확산을 중단시키는 박테리아 소통시스템  이성욱 2014/09/29 1296
951   단일 돌연변이가 망막 종양으로 이어지는 이유  이성욱 2014/09/29 1319
950   베를린 환자가 HIV 감염에서 완치된 이유  이성욱 2014/09/29 1459
949   유전자요법을 이용한 신경근육접합부 결함 치료  이성욱 2014/09/24 1659
948   전령 RNA에서의 슈도유리딜화  이성욱 2014/09/19 1693

[이전 10개] [1]..[11][12][13][14][15] 16 [17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN